Aspirin Decreases CRC Risk With High 15-PGDH Expression

Share this content:
Aspirin Decreases CRC Risk With High 15-PGDH Expression
Aspirin Decreases CRC Risk With High 15-PGDH Expression

(HealthDay News) -- Regular aspirin use is associated with a reduced risk of colorectal cancer in association with high hydroxyprostaglandin dehydrogenase 15-(nicotinamide adenine dinucleotide) (15-PGDH) expression, according to a study published in the April 23 issue of Science Translational Medicine.

Noting that aspirin use reduces the risk of colorectal neoplasia, Stephen P. Fink, PhD, from the Case Western Reserve University in Cleveland, and colleagues examined whether the effect would be antagonized by low 15-PGDH expression. 

They collected data on aspirin use every 2 years in the Nurses' Health Study and the Health Professionals Follow-Up Study and followed participants for diagnoses of colorectal cancer. Multivariable-adjusted hazard ratios for incident colorectal cancer were computed according to 15-PGDH messenger (mRNA) expression level, measured in normal mucosa from colorectal cancer resections.

RELATED: Gastrointestinal Cancers Resource Center

Among 127,865 participants, 15-PGDH mRNA expression could be assessed for 270 colorectal cancer cases. The researchers found that regular aspirin use correlated with a lower risk of colorectal cancer compared with nonuse, which developed within a background of colonic mucosa with high 15-PGDH expression (multivariable hazard ratio, 0.49; 95% confidence interval, 0.34 to 0.71), but not with low 15-PGDH expression (multivariable hazard ratio, 0.90; 95% confidence interval, 0.63 to 1.27) (P for heterogeneity = 0.018).

"This suggests that 15-PGDH expression level in normal colon mucosa may serve as a biomarker that may predict stronger benefit from aspirin chemoprevention," the researchers wrote.

One author disclosed financial ties to the pharmaceutical industry. One author is an inventor on a patent relating to the use of 15-PGDH levels for selection of individuals for chemoprevention with NSAID-type agents.


  1. Fink SP, Yamauchi M, Nishihara R, et al. Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of 15-Hydroxyprostaglandin Dehydrogenase (HPGD). Sci Transl Med. 2014;doi:10.1126/scitranslmed.3008481.

Related Resources

Related Slideshows

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs